Findings from plasmaMATCH Study
Findings from plasmaMATCH Study
For patients with breast cancer, plasmaMATCH study showed that Guardant360® assay has high sensitivity and detection rate and has sufficient clinical performance for adoption into routine clinical practice1.
Guardant360® testing showed 95% sensitivity overall for targeted sequencing and 100% sensitivity for patients with contemporaneous tissue biopsies1
Contemporaneous Paired Samples (within 60 days)
Guardant360® is able to detect mutations in genes that are clinically important in breast cancer: HER2, ESR1, and PIK3CA1
Mutation Detection Rate, %
Reference:
1. Turner NC, Kingston B, Kilburn LS, et. al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020 Oct;21(10):1296-1308. doi: 10.1016/S1470-2045(20)30444-7.
Address:
21 Biopolis Road,
# 03-28, Nucleos,
Singapore 138567.
Telephone:
+65 6018 8504
WhatsApp Hotline:
+65 8940 0360
Email:
clientservicesamea@guardanthealth.com
biopharma_AMEA@guardanthealth.com
Media inquiries:
Guardant Health Japan Corp.
Address:
9F Tokyo Portcity Takeshiba Office Tower,
1-7-1 Kaigan, Minato-ku,
Tokyo, 105-7590, Japan
© 2023 Guardant Health AMEA ALL RIGHTS RESERVED